Stock Analysis
- Australia
- /
- Medical Equipment
- /
- ASX:UBI
Universal Biosensors Full Year 2023 Earnings: AU$0.032 loss per share (vs AU$0.14 loss in FY 2022)
Universal Biosensors (ASX:UBI) Full Year 2023 Results
Key Financial Results
- Revenue: AU$6.63m (up 47% from FY 2022).
- Net loss: AU$6.74m (loss narrowed by 75% from FY 2022).
- AU$0.032 loss per share (improved from AU$0.14 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Universal Biosensors shares are down 6.3% from a week ago.
Risk Analysis
We should say that we've discovered 3 warning signs for Universal Biosensors (1 is a bit unpleasant!) that you should be aware of before investing here.
Valuation is complex, but we're helping make it simple.
Find out whether Universal Biosensors is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:UBI
Universal Biosensors
Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices used in healthcare (point-of-care), wine, food, and agriculture industries in Australia, the Americas, Europe, and internationally.
Excellent balance sheet with weak fundamentals.